Mersana Therapeutics IPO

6/27/2017

IPO

$75,000,000

Proceeds from the IPO will be used as follows: approximately $37.5 million for our Phase 1 clinical trial and ongoing development of XMT-1522, including clinical research outsourcing, drug manufacturing, companion diagnostic development and internal personnel costs; approximately $19.0 million for our preclinical activities and Phase 1 clinical trial of XMT-1536, including clinical research outsourcing, drug manufacturing, companion diagnostic development and internal personnel costs; and approximately $6.0 million for new and ongoing research activities, including for our platform, with the goal of filing one IND every 12 to 24 months.

Publicly-held

Biopharmaceutical

840 Memorial Dr.
Cambridge, MA 02139
USA

Mersana Therapeutics, Inc. (NASDAQ: MRSN) is focused on developing novel oncology agents based on Fleximer, a stealth material that enhances the pharmacokinetics and safety of drugs.